Skip to content
Archive

KOLINPHARMA®: first patent for XINEPA® in Israel and fifth outside Italy

Xinepa® is a nutraceutical product that already holds a double patent in Italy, for its technology and its formula, and has now had the innovation and uniqueness of its composition intended for the treatment of neuropathies and neuropathic pain recognised by one of the most advanced countries in the world in the nutraceutical market.

It is the result of research carried out by Kolinpharma®, which demonstrated its mechanism of action and validity through in vitro and clinical studies, the results of which have been published in international technical and scientific journals.

Rita Paola Petrelli, President of Kolinpharma®, comments: “Our strategy of competitive positioning in key countries outside Italy continues, through the certification of the most innovative products in our portfolio. Israel is a pioneering country, with high levels of control and restrictions, partly due to Kosher regulations; the new patent is a source of pride for us and a confirmation of the quality of our R&D work, with ever more innovative and effective products.”

Read the press release

More news

  1. KOLINPHARMA® al Convegno sulle Disfunzioni pelviperineali di Pavia
  2. KOLINPHARMA® “Leader della crescita 2021” per il terzo anno consecutivo
  3. KOLINPHARMA® and the “La Sapienza” University of Rome train the managers of the future
Archive